Table A2.
Analysis of synergy between AITC and DOCE calculated by survival rate for DU 145 cells.
| Docetaxel | AITC | Combination Treatment | Index 5 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dose | MSR 1 | p2,* | Dose | MSR 1 | p2,* | Expected 3 | Observed 4 | p 2,♦ | ||
| 24 h | 1 | 0.98 | >0.05 | 5 | 0.91 | <0.05 | 0.89 | 0.83 | >0.05 | 1.07 |
| 1 | 0.98 | >0.05 | 10 | 0.77 | <0.05 | 0.75 | 0.73 | >0.05 | 1.03 | |
| 1 | 0.98 | >0.05 | 15 | 0.67 | <0.05 | 0.66 | 0.63 | >0.05 | 1.05 | |
| 1 | 0.98 | >0.05 | 20 | 0.64 | <0.05 | 0.63 | 0.59 | >0.05 | 1.07 | |
| 2 | 0.75 | <0.05 | 5 | 0.91 | <0.05 | 0.68 | 0.67 | >0.05 | 1.01 | |
| 2 | 0.75 | <0.05 | 10 | 0.77 | <0.05 | 0.58 | 0.57 | >0.05 | 1.02 | |
| 2 | 0.75 | <0.05 | 15 | 0.67 | <0.05 | 0.5 | 0.49 | >0.05 | 1.02 | |
| 2 | 0.75 | <0.05 | 20 | 0.64 | <0.05 | 0.48 | 0.46 | >0.05 | 1.04 | |
| 48 h | 1 | 0.97 | >0.05 | 5 | 0.86 | <0.05 | 0.83 | 0.73 | <0.05 | 1.14 |
| 1 | 0.97 | >0.05 | 10 | 0.72 | <0.05 | 0.7 | 0.62 | <0.05 | 1.13 | |
| 1 | 0.97 | >0.05 | 15 | 0.6 | <0.05 | 0.58 | 0.54 | >0.05 | 1.07 | |
| 1 | 0.97 | >0.05 | 20 | 0.59 | <0.05 | 0.57 | 0.47 | <0.05 | 1.21 | |
| 2 | 0.75 | <0.05 | 5 | 0.86 | <0.05 | 0.65 | 0.56 | <0.05 | 1.16 | |
| 2 | 0.75 | <0.05 | 10 | 0.72 | <0.05 | 0.54 | 0.5 | >0.05 | 1.08 | |
| 2 | 0.75 | <0.05 | 15 | 0.6 | <0.05 | 0.45 | 0.45 | >0.05 | 1 | |
| 2 | 0.75 | <0.05 | 20 | 0.59 | <0.05 | 0.44 | 0.45 | >0.05 | 0.98 | |
| 72 h | 1 | 0.93 | >0.05 | 5 | 0.83 | <0.05 | 0.77 | 0.69 | <0.05 | 1.12 |
| 1 | 0.93 | >0.05 | 10 | 0.67 | <0.05 | 0.62 | 0.55 | <0.05 | 1.13 | |
| 1 | 0.93 | >0.05 | 15 | 0.54 | <0.05 | 0.5 | 0.46 | >0.05 | 1.09 | |
| 1 | 0.93 | >0.05 | 20 | 0.51 | <0.05 | 0.47 | 0.36 | <0.05 | 1.31 | |
| 2 | 0.65 | <0.05 | 5 | 0.83 | <0.05 | 0.54 | 0.47 | <0.05 | 1.15 | |
| 2 | 0.65 | <0.05 | 10 | 0.67 | <0.05 | 0.44 | 0.42 | >0.05 | 1.05 | |
| 2 | 0.65 | <0.05 | 15 | 0.54 | <0.05 | 0.35 | 0.36 | >0.05 | 0.97 | |
| 2 | 0.65 | <0.05 | 20 | 0.51 | <0.05 | 0.33 | 0.33 | >0.05 | 1 | |
Abbreviations: AITC, allyl isothiocyanate; DMSO, dimethyl sulfoxide; DOCE, docetaxel; MSR, Mean survival rate. 1 MSR of treated group/DMSO-treated control group. 2 p value was determined by one-way ANOVA followed by Tukey’s test. 3 Survival rate of DOCE group multiplied by survival rate of the AITC group. 4 Survival rate of combination treatment group (DOCE + AITC). 5 Index was calculated by dividing the expected survival rate by the observed survival rate. An index of >1 indicates synergistic effect and an index of <1 indicates less than additive effect. * p < 0.05, significantly different compared with control treatment. ♦ p < 0.05, comparison between expected and observed survival rate.